Table 2.

Associations of plasma levels of circulating lncRNAs and miRNAs with clinicopathological parameters of BC patients at diagnosis

Parameters	Plasma lncRNAs and miRNAs – P values
	H19	miR‐675	NEAT1	miR‐204	miR‐331
Correlations*
lncRNA/miRNA	0.007 (coefficient: 0.334)		0.070 (coefficient: −0.293)		–
BC patient subgroups vs. healthy women**
All	0.030 a	0.228	0.030 a	0.757	0.012 b
Neg. nodal status	0.033 a	0.067	0.045 a	0.632	0.031 b
Pos. nodal status	0.083	0.403	0.034 a	0.902	0.002 b
HER2‐pos. (ER‐neg./PR‐neg.)	0.008 a	0.375	0.412	0.051	0.043 b
TNBC (ER‐neg./PR‐neg./HER2‐neg.)	0.660	0.060	0.002 a	0.820	0.264
Differences between the BC patient subgroups**
Pos. vs. neg. lymph node status	0.430	0.004 a	0.092	0.684	0.192
TNBC vs. the other subgroups in which one or two or all receptors (ER, PR, HER2) are pos.	0.012 a	0.067	0.122	0.795	0.129
HER2‐pos. (ER‐neg./PR‐neg.) vs. the other receptor statuses	0.001 a	0.007 b	0.030 b	0.017 a	0.628
ER‐neg. vs. ER‐pos.	0.075	0.048	0.729	0.253	0.034
PR‐neg. vs. PR‐pos.	0.148	0.558	0.576	0.649	0.022
ER‐neg./PR‐neg. vs. the other subgroups	0.075	0.044	0.877	0.253	0.072
Recurrencec vs. primary	0.806	0.356	0.341	0.631	0.012 a

^aUpregulated, ^bDownregulated, ^cAt diagnosis. Significances in bold calculated by *Spearman‐Rho and **Mann–Whitney U‐test.